



EuroSIDA Newsletter

August 2025

Dear EuroSIDA Study Investigators,

The EuroSIDA Coordinating Centre sends many summer greetings to all our collaborators. We deeply appreciate your ongoing commitment to the study. Here are some of the updates we'd like to share with you:

Study Updates

Dataset 52

Dataset 52, Autumn 2024, was sent to almost 90 sites in 34 countries. Thank you for submitting your data and for meeting the December 2024 deadline. We are truly impressed by your continued commitment to EuroSIDA. Almost 9,000 forms were completed in REDCap, and REST data has been received from 3,000 active participants. In total, we have received data from approximately 12,000 participants. What a fantastic achievement!

Dataset 53

Dataset 53 will open on **1st September for REST sites and 1st October for REDCap sites**. A new variable on PrEP use before HIV diagnosis will be included in this dataset. All sites will receive a cover letter package with all the relevant study materials.

The deadline for data submission is **1st December 2025**, and we look forward to another successful data collection round with your continued support.

EuroSIDA Cabotegravir + Rilpivirine Enrolments

Earlier this year, an additional cohort was initiated with the support of ViiV Healthcare and the EuroSIDA Steering Committee. The cohort includes 500-750 non-EuroSIDA participants from existing EuroSIDA clinics who have started long-acting cabotegravir and rilpivirine (CAB+RPV). So far, 238 participants have been enrolled in the cohort across 11 countries with four sites already reaching their target enrolment. Only a few countries are still awaiting ethics approvals before they can begin enrolling participants. Hopefully, with your help and support,

we will reach our target of 750 CAB+RPV participants submitted by the end of 2025. Enrolment will remain open [until December 2025](#).

If your site is interested in participating in this substudy, please don't hesitate to contact the [EuroSIDA Coordinating Centre](#).

Please ensure that all injection dates are entered in the short REDCap form. We strongly encourage sites to complete the forms in real-time.

Important Update to EuroSIDA Study Procedures

As previously communicated by email, changes to EuroSIDA procedures will take effect due to reduced funding for cohort research in the coming years. The EuroSIDA Steering Committee approved these changes on 26 June 2025 and include:

- Discontinuation of plasma sample collection (for relevant sites) from 1 August 2025. Reimbursement will still be provided for samples collected up to this date.*
- Reduction in reimbursement for follow-up forms from 20 EUR to 15 EUR (applies to all EuroSIDA sites). This change will require a contract amendment, and the Coordinating Centre will contact each site individually about this change.

**Please note: These changes do not affect MISTRAL.*

We sincerely appreciate your understanding and flexibility in adapting to these changes. If you have any questions or concerns, please don't hesitate to contact the [EuroSIDA Coordinating Centre](#).

MISTRAL

MISTRAL enrolment closed in July 2024, with a total of 991 participants. Of these, 647 participants have completed visit 2. The aim is to complete the study by the end of this year, with clinical follow-up continuing until 2030. The team is currently developing a data catalogue to give researchers and EuroSIDA investigators a clearer overview of the types of data being collected within the MISTRAL study. This resource will support external researchers in preparing and submitting study proposals. The catalogue will be available on our website very soon.

For more information on the MISTRAL study [click here](#)

RESPOND

EuroSIDA remains the largest contributor of participants in RESPOND, with 15,000 participants. RESPOND presentations and publications can be found [here](#).

EuroSIDA Investigator Meeting in EACS, October 2025

We are pleased to confirm that the EuroSIDA and MISTRAL Investigator Meeting will take place during the EACS Conference in Paris:

Wednesday, 15 October 2025, 13:00-14:00 in Room 362/363

As part of our tradition of hosting annual investigator meetings, it is a pleasure to host this session again this year and to connect in person with our valued collaborators. An invitation email has already been sent to all sites. If you or your colleagues are attending EACS and did not receive the invitation, please let us know, and we will send you the Outlook invitation. Feel free to share the invitation with other EuroSIDA or MISTRAL team members at your centre who plan to attend the conference. We look forward to seeing many of you there!

Reminders

Reimbursement

We are currently in the reimbursement process for Dataset 52. All sites will receive payment after the summer. Further information will be shared in due time.

Data Processing Agreement (DPA)

As plasma sampling will be discontinued from 1 August 2025, we will also cease any ongoing DPA-related procedures.

Regulatory Approvals

We kindly urge you to **keep us informed of any updates** or progress from your respective ethics committees to facilitate the progress.

Staff Changes

Please inform us of any changes in staff or principal investigators at your site. This will allow us to update the study group and database accordingly.

Celebrating 30 years of EuroSIDA

In 2024, EuroSIDA marked its **30th anniversary**! To celebrate this incredible milestone, we've created a leaflet for study participants, thanking them for their longstanding contribution to

the study and highlighting key achievements from the past three decades. The leaflet will be shared with you soon. Kindly share it with participants, either by handing out printed copies or sharing the digital version at your site.

Thank you for helping us honour the people who make this research possible.

EuroSIDA Publications

The EuroSIDA study has reached **349 publications**! Seven manuscripts have been published since our last newsletter. Details of the latest publications in 2025 are listed below:

Publications in 2025

1. **Viremia does not independently predict cardiovascular disease in people with HIV: A RESPOND cohort study.** Elvstam O, Ryom L, Neesgaard B, Tau L, Günthard H F, Zangerle R, Vehreschild J J, Wit F, Sönnernborg A, Kovari H, Abutidze A, Petoumenos K, Jaschinski J, Hosein S, Bogner J, Grabmeier-Pfistershammer K, Garges H, Rooney J, Young L, Law M, Kirk O for the RESPOND Study Group.
Open Forum Infectious Diseases 2025. Jan 13;12(2):ofaf016.
2. **A simple tool to evaluate the effectiveness of HIV care for settings with gaps in data avail-ability (ESTIHIV).** Raben D, Jakobsen M L, Trajanovska J, Kowalska J, Vassilenko A, Dragas S, Harxhi A, Dragovic G J, Jaschinski N, Neesgaard B, Hjorth-Larsen K, Garges H, Gallant J, Lundgren J D, Philips A, Cam-biano V, Yazdanpanah Y and Mocroft A.
PLOS One 2025. Jan 29;20(1):e0316794.
3. **Incident tuberculosis in people with HIV across Europe from 2012-2022: Incidence rates, risk factors, and regional differences in a multicentre cohort study.** Kraef C, Roen A, Podle-kareva D, Bakowska E, Nemeth J, Knappik M, Payen M-C, Wit F, Mussini C, d'Arminio Monforte A, Castagna A, Chkhartishvili N, Neesgaard B, Jaschinski N, Volny Anne A, Borodulina E, Ballief M, Wallner E, Is-raelski D, Garges H, Mocroft A, Kirk O and the RESPOND Study Group.
European Respiratory Journal 2025. Feb 20:2401904.
4. **Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: An international, multicentre, observational cohort.** Han WM, Ryom L, Sabin C, Greenberg L, Cavassini M, Egle A, Duvivier C, Wit F, Mussini C, d'Arminio Monforte A, Castagna A, Miro JM, van der Valk M, Bonnet F, Pradier C, Skocic M, Matulionyte R, Stöckle M, Jaschinski N, Timiryasova A, Tallada J, Rogatto FP, Vannap-pagari V, Young LA, Lundgren JD, Petoumenos K, Hoy JF.
Clinical Infectious Diseases 2025. May 15:ciaf248.

All EuroSIDA publications can be found [here](#).

EuroSIDA Staff Update

Earlier this year, we said goodbye to two colleagues:

Olga Fursa

Olga joined CHIP in 2019 to support CARE and EuroSIDA projects in the Cohort Research team, contributing significantly to data quality and query management. She completed her PhD in 2024 and has since joined King's College London as Research Associate at the loPPN.

Erich Tusch

Erich joined CHIP in 2020 to support and analyze data from EuroSIDA and RESPOND while completing his PhD, which he defended December 2024. He is now working as a biostatistician at Statens Serum Institut (SSI), focusing on antimicrobial resistance.

We thank Olga and Erich for their valuable contributions and wish them all the best in their future careers.

We hope everyone in the EuroSIDA study is having a wonderful summer!

Thank you for a continuous rewarding, and successful collaboration.



Contact

Please always feel free to contact the EuroSIDA coordinating centre at eurosida.rigshospitalet@regionh.dk.

No question is too small or too big, we are happy to assist in all matters!

EuroSIDA Coordinating Centre

Rigshospitalet

CHIP, Section 2100

Blegdamsvej 9 · Copenhagen 2100 · Denmark